Back to top
more

TELESIS BIO (TBIO)

(Delayed Data from NSDQ)

$0.32 USD

0.32
23,010

0.00 (0.03%)

Updated Apr 25, 2024 03:58 PM ET

After-Market: $0.32 0.00 (-0.44%) 4:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -33.98% and 82.48%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 19.23% and 15.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Telesis Bio (TBIO) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study

by Zacks Equity Research

Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

by Zacks Equity Research

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Sweta Jaiswal, FRM headshot

Delta Variant Surge Brings Biotech ETFs in Focus

by Sweta Jaiswal, FRM

The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.

Will Translate Bio, Inc. (TBIO) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised

by Zacks Equity Research

Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.

Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug

by Zacks Equity Research

Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors

Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

by Zacks Equity Research

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

    Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug

    by Zacks Equity Research

    Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.

    Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

    by Zacks Equity Research

    Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

    Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon

    by Zacks Equity Research

    Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.

    Translate Bio, Inc. (TBIO) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -11.11% and -12.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Neena Mishra headshot

    Best Biotech Stocks & ETFs for mRNA, Gene Editing

    by Neena Mishra

    Here is what you should know about investing in these life changing technologies.

    Will Translate Bio, Inc. (TBIO) Report Negative Q1 Earnings? What You Should Know

    by Zacks Equity Research

    Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View

    by Zacks Equity Research

    Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.